 |
| 13-May-13 | Reiterated |
WallachBeth |
Hold |
$45 → $48 |
|
| 10-May-13 | Reiterated |
UBS |
Neutral |
$54 → $55 |
|
| 10-May-13 | Reiterated |
Mizuho |
Buy |
$60 → $66 |
|
| 01-Mar-13 | Reiterated |
Cantor Fitzgerald |
Buy |
$60 → $63 |
|
| 11-Jan-13 | Initiated |
RBC Capital Mkts |
Outperform |
$53 |
|
| 30-Nov-12 | Initiated |
Mizuho |
Buy |
$60 |
|
| 09-Aug-12 | Upgrade |
Cantor Fitzgerald |
Hold → Buy |
$50 → $60 |
|
| 30-Jul-12 | Downgrade |
Cantor Fitzgerald |
Buy → Hold |
$61 → $59 |
|
| 10-Apr-12 | Downgrade |
Auriga |
Buy → Hold |
|
|
| 28-Feb-12 | Upgrade |
Auriga |
Hold → Buy |
$55 |
|
| 10-Nov-11 | Reiterated |
Brean Murray |
Buy |
$50 → $53 |
|
| 21-Oct-11 | Reiterated |
JMP Securities |
Mkt Outperform |
$48 → $40 |
|
| 30-Sep-11 | Initiated |
Auriga |
Hold |
$30 |
|
| 20-Sep-11 | Reiterated |
UBS |
Neutral |
$40 → $32 |
|
| 06-May-11 | Reiterated |
UBS |
Neutral |
$37 → $39 |
|
| 29-Apr-11 | Initiated |
Brean Murray |
Buy |
$50 |
|
| 25-Feb-11 | Reiterated |
UBS |
Neutral |
$47 → $34 |
|
| 25-Feb-11 | Reiterated |
Stifel Nicolaus |
Buy |
$52 → $45 |
|
| 30-Sep-10 | Initiated |
UBS |
Neutral |
$45 |
|
| 14-Apr-10 | Initiated |
Thomas Weisel |
Overweight |
$52 |
|
|
|
| 17-May-13 01:04PM | SALIX PHARMACEUTICALS LTD Financials EDGAR Online Financials |
| 07:00AM | Salix Pharmaceuticals Outlines Data Presentations at Digestive Disease Week 2013 Business Wire |
| 16-May-13 06:00PM | Good News for Roche's Tarceva Zacks |
| 15-May-13 05:16PM | Good News for Novartis' Ilaris Zacks |
| 11:10AM | FDA Accepts Merck BLA Zacks |
| 09:55AM | Salix Stock Hits New 52-Week High (SLXP) at TheStreet |
| 14-May-13 09:45AM | Salix Beats on Earnings Zacks |
| 12-May-13 11:55AM | Investors are Digesting These Healthcare Stock Earnings Insights at Wall St. Cheat Sheet |
| 11-May-13 06:19PM | Salix Pharmaceuticals Ltd. Earnings Call Insights: Fulyzaq and Apriso at Wall St. Cheat Sheet |
| 10-May-13 05:19PM | The Gory Details on Salix Pharmaceuticals's Double Miss at Motley Fool +5.52% |
| 01:58PM | Priceline Is a Buy and 4 More Analyst Opinions To Know Now at Wall St. Cheat Sheet |
| 09-May-13 11:04PM | SALIX PHARMACEUTICALS LTD Files SEC form 10-Q, Quarterly Report EDGAR Online |
| 08:01PM | Salix Pharmaceuticals Management Discusses Q1 2013 Results - Earnings Call Transcript at Seeking Alpha |
| 05:04PM | Salix Pharmaceuticals Earnings: Heres Why Investors are Excited Now at Wall St. Cheat Sheet |
| 05:00PM | Salix Pharmaceuticals Inc Earnings Call scheduled for 5:00 pm ET today CCBN |
| 04:50PM | Salix Pharmaceuticals Inc Earnings Call scheduled for 5:00 pm ET today CCBN |
| 04:15PM | InPlay: Salix Pharma misses Q1 ests; guides Q2 EPS in-line; reaffirms FY13 guidance Briefing.com |
| 04:01PM | Salix Pharmaceuticals Reports 1Q2013 Results Business Wire |
| 09:38AM | SALIX PHARMACEUTICALS LTD Files SEC form 8-K, Results of Operations and Financial Condition, Other Events, Financial EDGAR Online |
| 08:07AM | Salix Pharmaceuticals Earnings Preview: Can This Streak Continue? at Wall St. Cheat Sheet |
| 07:34AM | Salix Pharmaceuticals Inc Earnings Call scheduled for 5:00 pm ET today CCBN |
| 07:07AM | Q1 2013 Salix Pharmaceuticals Inc Earnings Release - After Market Close CCBN |
| 07-May-13 07:00AM | Salix Pharmaceuticals to Present at BofA Merrill Lynch 2013 Health Care Conference Business Wire |
| 02-May-13 11:08AM | David Amsellem, Managing Director and Senior Research Analyst at Piper Jaffray & Co., Interviews with The Wall Street Transcript: Alternative Dosage Forms Create Barriers Against Competition in Generics Wall Street Transcript |
| 25-Apr-13 07:00AM | Salix Pharmaceuticals Announces 1Q2013 Financial Results Conference Call and Webcast Business Wire |
| 23-Apr-13 04:10PM | Sucampo Wins Approval for Expanded Use of Amitiza in U.S. at Bloomberg |
| 07:34AM | Sucampo Wins Approval for Expanded Use of Amitiza in U.S. at Bloomberg |
| 18-Apr-13 04:10PM | Santarus to Make Cash Milestone Payment Zacks |
| 11-Apr-13 04:59PM | Salix Pharmaceuticals Larger Than S&P 500 Component Cablevision Systems at Forbes |
| 20-Mar-13 04:18PM | Santarus' Uceris Data Published Zacks |
| 19-Mar-13 03:07AM | Strong Relistor Sales Drive New Rally In Progenics at Seeking Alpha |
| 15-Mar-13 12:47PM | Progenics 4Q loss narrows, revenue leaps AP |
| 11-Mar-13 01:02AM | Here's Why Salix Pharmaceuticals's Latest Report Might Worry You at Motley Fool |
| 06-Mar-13 01:04PM | SALIX PHARMACEUTICALS LTD Financials EDGAR Online Financials |
| 05-Mar-13 08:28AM | Salix Misses on Both Counts Zacks |
| 04-Mar-13 11:30AM | Best Buy Is an Underperform and 4 Stock Analyses to Know at Wall St. Cheat Sheet |
| 07:58AM | Earnings Beat at Endo Health Zacks |
| 03-Mar-13 02:54PM | 5 Stocks in the Trading Spotlight Post Earnings at Wall St. Cheat Sheet |
| 02-Mar-13 09:08PM | New Star Analyst Rankings for Salix Pharmaceuticals, Ltd. StarMine |
| 01-Mar-13 07:28PM | New Star Analyst Rankings for Salix Pharmaceuticals, Ltd. StarMine |
| 05:06PM | Bio-Reference Labs Reinitiated at Buy and 4 Reinitiated Ratings to Know Now at Wall St. Cheat Sheet |
| 02:38PM | Salix Pharmaceuticals Beats on EPS But GAAP Results Lag at Motley Fool |
| 01:08PM | Valeant Misses 4Q Estimates Zacks |
| 11:28AM | Impax Beats on Both Counts Zacks |
| 10:36AM | 3 New Analyst Research Notes Affecting These Stocks Now at Wall St. Cheat Sheet |
| 08:38AM | Auxilium Beats on All Fronts Zacks |
| 07:55AM | Salix price target raised to $53 from $44 at Brean Capital theflyonthewall.com |
| 06:07AM | SALIX PHARMACEUTICALS LTD Files SEC form 10-K, Annual Report EDGAR Online |
| 28-Feb-13 10:01PM | Salix Pharmaceuticals Management Discusses Q4 2012 Results - Earnings Call Transcript at Seeking Alpha |
| 06:18PM | Salix Pharmaceuticals Ltd. Earnings: Everything You Must Know Now at Wall St. Cheat Sheet |
| 04:47PM | SALIX PHARMACEUTICALS LTD Files SEC form 8-K, Results of Operations and Financial Condition, Other Events, Financial EDGAR Online |
| 04:01PM | Salix Pharmaceuticals Reports 4Q2012 and FY2012 Results Business Wire |
| 07:07AM | Q4 2012 Salix Pharmaceuticals Inc Earnings Release - After Market Close CCBN |
| 26-Feb-13 12:48PM | Valeant Acquires Targretin Rights Zacks |
| 11:10AM | Salix Pharma faces cautious trade optionMONSTER |
| 11:10AM | Salix Pharma faces cautious position optionMONSTER |
| 25-Feb-13 01:00PM | Salix Pharmaceuticals to Present at Two Investment Conferences in March Business Wire |
| 24-Feb-13 06:11AM | Synergy Targets Root Cause Of Irritable Bowel Syndrome at Seeking Alpha |
| 22-Feb-13 01:48PM | 4Q Beat for The Medicines Co. Zacks |
| 12:11PM | SP-333 Targets Root Cause Of Irritable Bowel Syndrome at Motley Fool |
| 21-Feb-13 10:18AM | Capital One Valuation Deemed Outstanding and 4 Stock Analyses Turning Heads at Wall St. Cheat Sheet |
| 20-Feb-13 04:08PM | Santarus Launches Uceris in the US Zacks |
| 15-Feb-13 04:36PM | SALIX PHARMACEUTICALS LTD Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online |
| 14-Feb-13 07:00AM | Salix Pharmaceuticals Announces 4Q2012 and FY2012 Financial Results Conference Call and Webcast Business Wire |
| 13-Feb-13 10:39AM | New York & Company Raised Following Celeb Signing and 4 Stock Analyses Attracting Attention at Wall St. Cheat Sheet |
| 12-Feb-13 04:47PM | SALIX PHARMACEUTICALS LTD Files SEC form 8-K, Other Events EDGAR Online |
| 04:18PM | UCB, Amgen Discontinue Study Zacks |
| 08-Feb-13 09:28AM | Wider-Than-Expected Loss at Avanir Zacks |
| 06-Feb-13 03:43PM | Good News for UCB Zacks |
| 04-Feb-13 09:08AM | Valeant Closes Natur Acquisition Zacks |
| 31-Jan-13 02:23PM | AUXL Files Patent Infringement Suit Zacks |
| 30-Jan-13 05:48PM | Data on Anacor Candidate Zacks |
| 03:08PM | ARIAD Closes Offering of Shares Zacks |
| 29-Jan-13 12:28PM | Data From SGEN on Cancer Candidate Zacks |
| 28-Jan-13 04:01AM | Salix Pharmaceuticals Ltd. Stock Upgraded (SLXP) at TheStreet |
| 23-Jan-13 05:48PM | EU Nod for Novo Nordisk Drugs Zacks |
| 04:18PM | Positive CHMP Opinions for Novartis Zacks |
| 03:58PM | CRL for Impax' Rytary Zacks |
| 22-Jan-13 09:21PM | Keep Your Eye On Earnings This Week at Seeking Alpha |
| 18-Jan-13 01:08PM | Onyx to Raise Funds Zacks |
| 16-Jan-13 01:58PM | FDA will miss target decision date on Hyperion drug at bizjournals.com |
| 15-Jan-13 07:15PM | Raleigh-Cary one of 14 markets in nation to leave recession behind at bizjournals.com |
| 11-Jan-13 01:55PM | Wabtec Initiated at Hold and 3 Initiated Stocks on the Move at Wall St. Cheat Sheet |
| 06:31AM | Salix initiated with an Outperform at RBC Capital at theflyonthewall.com |
| 12:54AM | Coverage initiated on Salix Pharma by RBC Capital Mkts Briefing.com |
| 10-Jan-13 04:34PM | SALIX PHARMACEUTICALS LTD Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online |
| 09-Jan-13 09:16AM | Salix stock struggles to gain traction at bizjournals.com |
| 07-Jan-13 12:18PM | FDA Approval for Salix Drug Zacks |
| 03-Jan-13 06:59AM | Cornerstone, Pozen among market winners at bizjournals.com |
| 06:55AM | BofA, Citigroup, Ford, HP most active yesterday as the bulls ran at bizjournals.com |
| 02-Jan-13 04:43PM | Cornerstone, Pozen run with bull market at bizjournals.com |
| 02:29PM | FDA Approves Salix Pharmaceuticals' Fulyzaq for HIV/AIDS Patients at Motley Fool |
| 10:30AM | Caterpillar, Salix among local gainers in hot market at bizjournals.com |
| 07:03AM | Salix says FDA approves Fulyzaq 125mg delayed-release tablets at theflyonthewall.com |
| 07:02AM | InPlay: Salix Pharma announced FDA approved Fulyzaq 125 mg delayed-release tablets for the symptomatic relief of diarrhea in patients with HIV/AIDS on anti-retroviral therapy Briefing.com |
| 07:01AM | FDA Approves Fulyzaq (Crofelemer) 125 mg Delayed-Release Tablets for the Symptomatic Relief of Diarrhea in Patients with HIV/AIDS on Anti-Retroviral Therapy (ART) Business Wire |
| 07:00AM | Salix Pharmaceuticals to Present at J.P. Morgan Healthcare Conference Business Wire |
| 31-Dec-12 05:58PM | J&J Gets FDA Approval for Sirturo, Lexicon Wins Fast Track for LX1033: Healthcare Business Update at Wall St. Cheat Sheet |
| 05:13PM | Anti-diarrheal drug for HIV patients, made from South American tree bark, approved by FDA at bizjournals.com |
| 01:56PM | Salix Wins FDA Approval of Dragons Blood Drug for Diarrhea at Bloomberg |
|
|
| Salix Pharmaceuticals, Ltd. acquires, develops, and commercializes prescription drugs and medical devices used in the treatment of various gastrointestinal diseases in the United States. The company offers XIFAXAN tablets for the treatment of patients with travelers' diarrhea, and for overt hepatic encephalopathy; MOVIPREP and OSMOPREP for cleansing of the colon as a preparation for colonoscopy in adults; APRISO for the maintenance of remission of ulcerative colitis; RELISTOR for the treatment of opioid-induced constipation (OIC) in patients with advanced illness; and SOLESTA for the treatment of fecal incontinence; DEFLUX for the treatment of vesicoureteral reflux. It also provides FULYZAQ for the symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS on anti-retroviral therapy; GIAZO for the treatment of mildly to moderately active ulcerative colitis in males; and METOZOLV ODT for the treatment of symptomatic documented gastroesophageal reflux disease (GERD) that fails to respond to conventional therapy. Its products also comprise AZASAN azathioprine Tablets, which are used as adjunct for the prevention of rejection in renal homotransplantations and to reduce signs and symptoms of severe active rheumatoid arthritis; ANUSOL-HC and PROCTOCORT for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses; and PEPCID for the short-term treatment of GERD, active duodenal ulcer, active benign gastric ulcer, erosive esophagitis due to GERD, and peptic ulcer diseases. In addition, the company provides DIURIL for the treatment of hypertension and also as adjunctive therapy in edema associated with congestive heart failure, cirrhosis of the liver, corticosteroid and estrogen therapy, and kidney diseases; and COLAZAL for mildly to moderately active ulcerative colitis. The company was founded in 1989 and is headquartered in Raleigh, North Carolina. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Sirgo Mark A | Director | May 03 | Sale | 54.00 | 2,008 | 108,432 | 31,057 | May 07 05:46 PM | | KEANE WILLIAM P | Director | Apr 15 | Option Exercise | 15.25 | 30,000 | 457,398 | 63,202 | Apr 17 05:06 PM | | KEANE WILLIAM P | Director | Apr 15 | Sale | 49.44 | 30,000 | 1,483,200 | 33,202 | Apr 17 05:06 PM | | Forbes William P | EVP Research&Devel & CDO | Apr 10 | Option Exercise | 17.53 | 13,000 | 227,890 | 80,191 | Apr 12 05:05 PM | | Forbes William P | EVP Research&Devel & CDO | Apr 10 | Sale | 49.37 | 8,673 | 428,186 | 71,518 | Apr 12 05:05 PM | | D ALONZO THOMAS | Director | Apr 08 | Option Exercise | 7.60 | 15,000 | 114,000 | 90,640 | Apr 10 04:25 PM | | D ALONZO THOMAS | Director | Apr 08 | Sale | 49.57 | 6,186 | 306,670 | 84,454 | Apr 10 04:25 PM | | Sirgo Mark A | Director | Mar 20 | Sale | 50.05 | 3,000 | 150,150 | 28,955 | Mar 22 06:40 PM | | Scruggs Rick D | Executive Vice President | Mar 07 | Sale | 49.69 | 2,000 | 99,380 | 48,566 | Mar 08 04:54 PM | | Scruggs Rick D | Executive Vice President | Mar 06 | Sale | 49.34 | 5,000 | 246,700 | 50,566 | Mar 08 04:54 PM | | Sirgo Mark A | Director | Jan 11 | Sale | 46.19 | 3,000 | 138,570 | 31,955 | Jan 15 04:19 PM | | CHAPPELL JOHN F | Director | Jan 03 | Option Exercise | 7.60 | 15,000 | 114,000 | 450,224 | Jan 07 04:38 PM | | DERBYSHIRE ADAM C | EVP Finance/CFO | Dec 26 | Option Exercise | 8.00 | 90,000 | 720,000 | 236,601 | Dec 28 04:38 PM | | DERBYSHIRE ADAM C | EVP Finance/CFO | Dec 26 | Sale | 41.44 | 60,000 | 2,486,382 | 176,601 | Dec 28 04:38 PM | | LOGAN CAROLYN J | President & CEO | Dec 20 | Option Exercise | 7.60 | 33,750 | 256,500 | 660,881 | Dec 21 04:32 PM | | LOGAN CAROLYN J | President & CEO | Dec 20 | Sale | 42.27 | 25,000 | 1,056,673 | 635,881 | Dec 21 04:32 PM | | CHAPPELL JOHN F | Director | Dec 04 | Sale | 42.53 | 3,000 | 127,590 | 435,224 | Dec 06 04:37 PM | | CHAPPELL JOHN F | Director | Nov 21 | Sale | 41.62 | 3,000 | 124,860 | 438,224 | Nov 26 04:22 PM | | CHAPPELL JOHN F | Director | Nov 14 | Sale | 41.15 | 3,000 | 123,450 | 441,224 | Nov 16 04:50 PM | | Sirgo Mark A | Director | Nov 13 | Sale | 40.75 | 1,725 | 70,294 | 34,955 | Nov 13 06:50 PM | | Sirgo Mark A | Director | Nov 12 | Sale | 40.30 | 1,725 | 69,518 | 36,680 | Nov 13 06:50 PM | | LOGAN CAROLYN J | President & CEO | Jun 28 | Option Exercise | 4.07 | 228,467 | 929,861 | 763,788 | Jul 02 05:01 PM | | LOGAN CAROLYN J | President & CEO | Jun 28 | Sale | 52.07 | 119,300 | 6,211,832 | 644,488 | Jul 02 05:01 PM | | LOGAN CAROLYN J | President & CEO | Jun 14 | Option Exercise | 4.07 | 36,534 | 148,693 | 535,321 | Jun 18 04:28 PM | | D ALONZO THOMAS | Director | Jun 08 | Sale | 51.63 | 2,550 | 131,657 | 0 | Jun 12 04:29 PM | | D ALONZO THOMAS | Director | Jun 08 | Sale | 51.63 | 7,000 | 361,410 | 75,640 | Jun 12 04:29 PM | | KEANE WILLIAM P | Director | Jun 05 | Sale | 51.67 | 10,000 | 516,692 | 33,202 | Jun 07 04:40 PM | | CHAPPELL JOHN F | Director | Jun 01 | Sale | 51.49 | 3,000 | 154,470 | 406,504 | Jun 05 04:28 PM |
|
|
|
|
|
|
